US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,327.58

-9.1315-0.68%

Number of Gainers:5

Number of Losers:15

Number of Flat:- -

PE:- -

High:1,343.21

Open:1,342.69

Low:1,326.57

Close:1,336.71

Loading ...

TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks

TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years

Novavax Announces Significantly Improved Terms for Collaboration and License Agreement With Takeda for Nuvaxovid® in Japan

THOMSON REUTERS

Novavax Inc - Updated Agreement Includes Upfront Payment and Annual Milestones Related to Regulatory Approvals & Royalties on Net Sales Earned

THOMSON REUTERS

Novavax Inc - Nuvaxovid to Remain Available in Japan

THOMSON REUTERS

Ibio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy With Glp-1S in Preclinical Model

THOMSON REUTERS

iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

Press Release: Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress

Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan

BioNTech Posts Wider 1Q Loss, to Focus on Oncology Programs

BioNTech Reports Q1 2025 Financial Results and Strategic Oncology Advancements

BioNTech Names Ramon Zapata-Gomez as Chief Financial Officer

MT Newswires Live

BioNTech Names Zapata-Gomez Financial Chief

Press Release: BioNTech Announces First Quarter 2025 Financial Results and Corporate Update

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

Deutsche Pfandbriefbank (0R9K) Gets a Buy from Warburg Research

BUZZ-India's Biocon gains on unit getting marketing access for Yesintek therapy in US

Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

3 Cash-Heavy Stocks in the Doghouse

iBio, Inc. Reports Strong Q3 2025 Progress

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4568/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1327.5806,"timestamp":1746820799999,"preClose":1336.712,"halted":0,"volume":113582454,"delay":0,"changeRate":-0.006831,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-9.13147,"latestTime":"05-09 16:00:00 EDT","open":1342.69,"high":1343.2052,"low":1326.5701,"amount":4653162209.902576,"amplitude":0.012445,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.565313,"peRate":21.186942,"turnoverRate":0.007317,"increases":5,"decrements":15,"flats":0,"marketCap":1093969830401.5,"floatMarketCap":1075897192963},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1343.2052,"amplitude":0.012445,"preClose":1336.712,"low":1326.5701,"pbRate":"3.565313","latestPrice":1327.5806,"volume":113582454,"delay":0,"open":1342.69,"prevYearClose":1274.8187,"prevWeekClose":1375.2667,"prevMonthClose":1374.5028,"prevQuarterClose":1427.887,"fiveDayClose":1375.2667,"twentyDayClose":1281.7616,"sixtyDayClose":1380.7908,"secType":"PLATE","market":"US","turnoverRate":0.007317,"peRate":21.186942,"marketCap":1093969830401.5,"floatMarketCap":1075897192963,"timestamp":1746820799999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":5,"down":15,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533158603","title":"TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2533158603","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533158603?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:05","pubTimestamp":1746446700,"startTime":"0","endTime":"0","summary":"TREMFYA subcutaneous induction demonstrates significant rates of clinical remission and endoscopic improvement at Week 24 in ulcerative colitis. Findings build on recent FDA-approval of both routes of administration for induction therapy with TREMFYA in Crohn's disease. SAN DIEGO, May 5, 2025 /PRNewswire/ -- Johnson & Johnson  today announced new data from the Phase 3 ASTRO study evaluating TREMFYA  subcutaneous  induction therapy in adults with moderately to severely active ulcerative colitis . The ASTRO Week 24 data build on the Week 12 SC induction data that showed statistically significant and clinically meaningful improvements compared to placebo across all clinical and endoscopic measures consistent with the U.S. Food and Drug Administration -approved intravenous  induction regimen evaluated in this population, in the Phase 3 QUASAR study.1,2 TREMFYA is the first and only IL-23 inhibitor to demonstrate robust results with a fully SC regimen. These findings are among 24 abstracts ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/tremfya-guselkumab-positioned-become-first-120500064.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tremfya-guselkumab-positioned-become-first-120500064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B1BXHZ80.USD","BK4568","BK4588","LU1066051811.HKD","CD","BK4504","IE0009355771.USD","LU1674673691.USD","LU2505996509.AUD","LU2347655156.SGD","LU0792757196.USD","LU2505996681.GBP","SG9999002232.USD","LU1674673428.USD","LU2089984988.USD","BK4116","IE0002270589.USD","LU0640476718.USD","IE00B19Z3B42.SGD","IE00BFTCPJ56.SGD","LU0345770993.USD","IE00B42XCP33.USD","LU1914381329.SGD","LU0345770308.USD","LU1894683348.USD","LU1032955483.USD","LU2129689514.USD","LU2468319806.SGD","IE00BSNM7G36.USD","LU1267930813.SGD","LU1718418525.SGD","LU1935042991.SGD","LU1196500208.SGD","LU1244550494.USD","LU1929549753.HKD","JNJ","LU1778281490.HKD","LU1894683264.USD","BK4559","IE00BLSP4239.USD","IE00B2B36J28.USD","LU0466842654.USD","BK4581","LU1732800096.USD","IE00B7SZLL34.SGD","LU0320765646.SGD","LU1280957306.USD","LU1244550221.USD","LU0345769631.USD","LU0889566641.SGD"],"gpt_icon":0},{"id":"2533056586","title":"TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years","url":"https://stock-news.laohu8.com/highlight/detail?id=2533056586","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533056586?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:05","pubTimestamp":1746446700,"startTime":"0","endTime":"0","summary":"Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92. SAN DIEGO, Calif., May 5, 2025 /PRNewswire/ -- Johnson & Johnson  today announced new data from the TREMFYA  Phase 3 QUASAR long-term extension  study in adults with moderately-to-severely active ulcerative colitis . These data are among 24 abstracts highlighting the Company's research being presented at Digestive Disease Week  2025.Data from the QUASAR LTE studydemonstrate patients treated with TREMFYA sustained clinical and endoscopic efficacy at Week 92: a, 1. 72% of patients were in clinical remissionb with 99% of those patients remaining corticosteroid free for 8 or more weeks through Week 92.Patients treated with TREMFYA sustained clinical and endoscopic remission regardless of prior biologic and/or JAK inhibitor treatment history.\"With these findings, TREMFYA shows the powerful impact it can have in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/tremfya-guselkumab-delivers-sustained-clinical-120500832.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tremfya-guselkumab-delivers-sustained-clinical-120500832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4504","LU2505996509.AUD","LU1032955483.USD","LU0345770308.USD","LU0889566641.SGD","IE00BFTCPJ56.SGD","LU1244550494.USD","LU1674673428.USD","LU1244550221.USD","LU0345770993.USD","LU1778281490.HKD","LU0466842654.USD","LU1935042991.SGD","LU1066051811.HKD","LU0640476718.USD","LU2089984988.USD","IE00B2B36J28.USD","LU0792757196.USD","BK4588","LU1929549753.HKD","IE00B7SZLL34.SGD","LU1674673691.USD","IE00B1BXHZ80.USD","IE00BSNM7G36.USD","IE0009355771.USD","IE00B19Z3B42.SGD","SG9999002232.USD","BK4581","LU2347655156.SGD","BK4568","LU2468319806.SGD","IE0002270589.USD","JNJ","LU0345769631.USD","LU1267930813.SGD","IE00B42XCP33.USD","IBD","LU1718418525.SGD","CD","LU1196500208.SGD","LU1732800096.USD","LU0320765646.SGD","LU1894683348.USD","LU1914381329.SGD","LU2505996681.GBP","BK4116","LU1280957306.USD","BK4559","IE00BLSP4239.USD","LU1894683264.USD"],"gpt_icon":0},{"id":"2533586869","title":"Novavax Announces Significantly Improved Terms for Collaboration and License Agreement With Takeda for Nuvaxovid® in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2533586869","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533586869?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446407,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nTUABYWNX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4585","NVAX","BK4588","BK4547","BK4139"],"gpt_icon":0},{"id":"2533586856","title":"Novavax Inc - Updated Agreement Includes Upfront Payment and Annual Milestones Related to Regulatory Approvals &  Royalties on Net Sales Earned","url":"https://stock-news.laohu8.com/highlight/detail?id=2533586856","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533586856?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446407,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nTUABYWNX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4585","BK4568","NVAX","BK4547","BK4139"],"gpt_icon":0},{"id":"2533586842","title":"Novavax Inc - Nuvaxovid to Remain Available in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2533586842","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533586842?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446407,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nTUABYWNX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4585","BK4568","NVAX","BK4547","BK4139"],"gpt_icon":0},{"id":"2533810586","title":"Ibio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy With Glp-1S in Preclinical Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2533810586","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533810586?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nTUA9G4QRW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IBIO","BK4568"],"gpt_icon":0},{"id":"2533589745","title":"iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2533589745","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533589745?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446400,"startTime":"0","endTime":"0","summary":"Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fat depots, which are strongly linked to increased risk of cardiovascular and metabolic diseases, resulting in a 26% reduction in fat mass with no loss in muscle. Strong synergistic effect on fat mass  was observed when the Activin E antibody was combined with a GLP-1 receptor agonist, resulting in total weight loss of 35.3%, 7.5% greater than GLP-1 alone. SAN DIEGO, May 05, 2025  -- iBio, Inc., an AI-driven innovator of precision antibody therapies, today announced new promising preclinical data for its first-in-class Activin E antibody unveiled in January. Data from the recently completed 4-week study in diet-induced obese mice show a 26% reduction in fat mass following treatment with the Activin E antibody, with muscle mass fully preserved. These findings highlight a significant fat loss can be achieved without the double-digit weight reductions typically required by other obesity drugs.iB","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ibio-first-class-activin-e-120000623.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","GLP","BK4139","IBIO","BK4590","BK4144"],"gpt_icon":0},{"id":"2533585772","title":"Press Release: Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2533585772","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533585772?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446400,"startTime":"0","endTime":"0","summary":"Urges Stockholders to Vote FOR Reverse Stock Split Proposal at Upcoming Annual Meeting as Recommended by Leading Independent Proxy Advisory Firms. SOUTH SAN FRANCISCO, Calif., May 05, 2025  -- Vaxart, Inc.  today issued the following letter to its stockholders from its President & Chief Executive Officer, Steven Lo.We are writing to update you on recent developments that positively impact Vaxart's ability to advance our promising vaccine candidates and highlight the importance of remaining listed on Nasdaq in order to maintain our progress. We would greatly appreciate your voting \"FOR\" the reverse stock split proposal to continue our momentum at this critical time.Concurrently, in light of the challenging environment, we continue to take prudent measures to control costs in order to best position the Company for future success. Accordingly, we recently implemented another round of strategic cost reductions  that assisted in extending cash runway into 2026, allowing us to deliver on mul","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4600","BK4023","BK4568","BK4585","LU2065732104.USD","BK4595","BK4588","STRK","BK4596","NQmain","PRGS","BK4139","BK4516","VXRT","BK4097"],"gpt_icon":1},{"id":"2533581858","title":"Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2533581858","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533581858?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446400,"startTime":"0","endTime":"0","summary":"Improved financial terms forNovavax and streamlined operations will help both companies better meet the needs of the Japanese market. Forward-Looking Statements|Statements herein relating to the future of Novavax, its operating plans and prospects, the possible achievement of additional milestones under the CLA, and our ability to operate effectively in the Japanese market, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, antigenic drift or shift in the SARS-CoV-2 spike protein, challenges satisfying, alone or together with partners, various safety, efficacy and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obta","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/novavax-announces-significantly-improved-terms-120000485.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novavax-announces-significantly-improved-terms-120000485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BNTX","BK4568","BK4585","BK4551","BK4548","BK4547","BK4535","BK4588","BK4139","NVAX"],"gpt_icon":0},{"id":"2533764588","title":"BioNTech Posts Wider 1Q Loss, to Focus on Oncology Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2533764588","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533764588?lang=en_us&edition=fundamental","pubTime":"2025-05-05 19:21","pubTimestamp":1746444060,"startTime":"0","endTime":"0","summary":"BioNTech logged a hefty first-quarter loss and said it would focus on promising oncology programs from now on, citing risks to its current franchise from public policy and opinion.BioNTech, of Mainz, Germany, posted a loss of 415.8 million euro , or EUR1.73 a share, compared with EUR315.1 million, or EUR1.31 a share, a year earlier.First-quarter revenue fell 2.6% to EUR182.8 million, short of the average Wall Street target of 198.8 million euro.The company, which rose to fame when it partnered with Pfizer on a Covid 19 vaccine, said the vaccine sales followed a seasonal pattern in the first quarter.For 2025, BioNTech targets revenue in a range between EUR1.7 billion and EUR2.2 billion, following a similar pattern in 2024, with sales concentrated in the last three to four months.\"Potential changes to the law or governmental policy, including tariffs and public-health policy, and evolving public sentiment worldwide, could further negatively impact our anticipated revenues and expenses,\" ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BNTX","BK4585","BK4588","BK4139","BK4535","BK4548","BK4551"],"gpt_icon":0},{"id":"2533458381","title":"BioNTech Reports Q1 2025 Financial Results and Strategic Oncology Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2533458381","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533458381?lang=en_us&edition=fundamental","pubTime":"2025-05-05 19:17","pubTimestamp":1746443835,"startTime":"0","endTime":"0","summary":"The latest update is out from BioNTech SE ( ($BNTX) ). On May 5, 2025, BioNTech SE announced its financial results for the first quarter of 2025, r...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biontech-reports-q1-2025-financial-results-and-strategic-oncology-advancements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biontech-reports-q1-2025-financial-results-and-strategic-oncology-advancements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","BK4535","BK4551","BK4568","BK4585","BK4588","BNTX","BK4139"],"gpt_icon":0},{"id":"2533758863","title":"BioNTech Names Ramon Zapata-Gomez as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2533758863","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533758863?lang=en_us&edition=fundamental","pubTime":"2025-05-05 19:12","pubTimestamp":1746443529,"startTime":"0","endTime":"0","summary":"BioNTech (BNTX) said Monday it has appointed Ramon Zapata-Gomez as chief financial officer, effective July 1, succeeding Jens Holstein, who will retire June 30.Before joining BioNTech, Zapata-Gomez served as CFO of BioMedical Research at Novartis (NVS), the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B4R5TH58.HKD","BK4139","BNTX","IE0002141913.USD","IE00B2B36J28.USD","BK4568","LU0208291251.USD","BK4535","NVS","IE00BFTCPJ56.SGD","BK4532","IE00BJT1NW94.SGD","IE0009355771.USD","BK4578","BK4007","LU0320765489.SGD","BK4588","BK4548","BK4585","LU0211331839.USD","BK4551","IE00BJJMRZ35.SGD","LU0070302665.USD"],"gpt_icon":0},{"id":"2533300693","title":"BioNTech Names Zapata-Gomez Financial Chief","url":"https://stock-news.laohu8.com/highlight/detail?id=2533300693","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533300693?lang=en_us&edition=fundamental","pubTime":"2025-05-05 18:54","pubTimestamp":1746442440,"startTime":"0","endTime":"0","summary":"BioNTech, the German biotech that rose to fame when it partnered with Pfizer on a Covid 19 vaccine, named Novartis executive Ramón Zapata-Gomez as chief financial officer, succeeding Jens Holstein upon the latter's retirement in June.The company had previously disclosed Holstein's plans to retire on June 30, at which time Zapata-Gomez, who has served as the chief financial officer of Swiss drug maker's Novartis's biomedical research unit since 2022.Zapata-Gomez's experience will help BioNTech reinvent itself as a multi-product company with an emphasis on oncology, the company said. In addition to his work at Novartis, Zapata-Gomez has held financial positions at generic-drug maker Sandoz AG, and consumer-products giant Mondelēz International.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002224.SGD","SG9999003800.SGD","LU1894683348.USD","SG9999002232.USD","LU0058720904.USD","SG9999001176.SGD","IE0002270589.USD","LU0868494617.USD","IE00B19Z3581.USD","LU0289739699.SGD","SG9999001176.USD","IE00B19Z3B42.SGD","BK4550","BK4588","LU0170899867.USD","BK4007","LU1066053197.SGD","LU0225284248.USD","LU1023059063.AUD","LU1057294990.SGD","IE000M9KFDE8.USD","BK4585","BK4581","BK4534","SG9999013999.USD","LU0234572021.USD","BK4599","LU0456855351.SGD","LU0321505439.SGD","LU0985481810.HKD","IE00BBT3K403.USD","BK4592","IE00BLSP4452.SGD","BK4533","LU0122379950.USD","LU1066051498.USD","LU0306806265.USD","LU1894683264.USD","SG9999011175.SGD","BK4568","IE00BLSP4239.USD","LU0321505868.SGD","LU0306807586.USD","LU0225771236.USD","SGXZ57979304.SGD","LU1883839398.USD"],"gpt_icon":1},{"id":"2533300374","title":"Press Release: BioNTech Announces First Quarter 2025 Financial Results and Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2533300374","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533300374?lang=en_us&edition=fundamental","pubTime":"2025-05-05 18:45","pubTimestamp":1746441900,"startTime":"0","endTime":"0","summary":"-- Continued oncology pipeline advancement with a strategic focus on two. bispecific antibody targeting PD-L1 and VEGF-A1, and mRNA cancer. -- Presented multiple clinical updates across oncology pipeline underlining. BioNTech's combination strategy in oncology with first data presented for. the novel combination of BNT327 plus antibody-drug conjugates . -- Development and commercial preparation for a 2025/2026 season. -- First quarter 2025 revenues of EUR0.2 billion2, net loss of EUR0.4. equivalents and security investments as of March 31, 20254. in millions EUR, except per share     First Quarter  First Quarter. Revenues reported were EUR182.8 million for the three months ended March 31, 2025, compared to EUR187.6 million for the comparative prior year period. Revenues during the first quarter of 2025 were mainly driven by revenues derived from BioNTech's COVID-19 vaccine collaboration.Cost of sales were EUR83.8 million for the three months ended March 31, 2025, compared to EUR59.1 mi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4551","L","LU0053666078.USD","BK4107","BK4568","BK4588","BK4139","BNTX","BK4535","BK4585"],"gpt_icon":0},{"id":"2533586096","title":"NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC","url":"https://stock-news.laohu8.com/highlight/detail?id=2533586096","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533586096?lang=en_us&edition=fundamental","pubTime":"2025-05-05 18:30","pubTimestamp":1746441000,"startTime":"0","endTime":"0","summary":"Shelton, Connecticut-- - NanoViricides, Inc. , , a leading clinical stage global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.Anil R. Diwan, President & Executive Chairman, will be hosting one-on-one meetings on May 14th from 9:00 A.M. to 3:00 P.M. .To register for one-on-one meetings with management at The Plaza Hotel in New York City, interested parties should contact John Perez at jperez@dboralcapital.com.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nanoviricides-inc-announces-participation-d-103000436.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nanoviricides-inc-announces-participation-d-103000436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4568","BK4233","BK4590","BK4561","BK4144","ET","NNVC","BK4585","BK4160","BK4581","BK4588","NYC"],"gpt_icon":0},{"id":"2533306398","title":"Deutsche Pfandbriefbank (0R9K) Gets a Buy from Warburg Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2533306398","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533306398?lang=en_us&edition=fundamental","pubTime":"2025-05-05 16:37","pubTimestamp":1746434237,"startTime":"0","endTime":"0","summary":"In a report released today, Andreas Plaesier from Warburg Research maintained a Buy rating on Deutsche Pfandbriefbank (0R9K – Research Report), wit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/deutsche-pfandbriefbank-0r9k-gets-a-buy-from-warburg-research?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/deutsche-pfandbriefbank-0r9k-gets-a-buy-from-warburg-research?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BNTX","PBBGF","BK4548","BK4535","BK4551","BK4588","BK4229","BK4585","BK4195","BK4568"],"gpt_icon":0},{"id":"2533370716","title":"BUZZ-India's Biocon gains on unit getting marketing access for Yesintek therapy in US","url":"https://stock-news.laohu8.com/highlight/detail?id=2533370716","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533370716?lang=en_us&edition=fundamental","pubTime":"2025-05-05 15:14","pubTimestamp":1746429297,"startTime":"0","endTime":"0","summary":"BUZZ-India's Biocon gains on unit getting marketing access for Yesintek therapy in US** Biocon BION.NS climbs 4.4% to 332.80 rupees** Drugmaker's unit Biocon Biologics gets marketing access for its immunotherapy drug Yesintek - Biocon's biosimilar for Janssen Biotech's Stelara - in the U.S.** The therapy, chemically called ustekinumab, is used for treating patients with chronic plaque psoriasis** Stock rated \"buy\" on avg; median PT is 400 rupees, per data compiled by LSEG** Session's gains trim BION's YTD losses to 8.9%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nL4N3RD055:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","LU0889566641.SGD","LU2089984988.USD","IE00B4R5TH58.HKD","IE00B19Z3B42.SGD","LU0345769128.USD","LU1894683348.USD","LU1261432733.SGD","IE00BSNM7G36.USD","JNJ","LU1778281490.HKD","LU0203347892.USD","LU1585245621.USD","LU2430703178.SGD","LU2505996681.GBP","LU2112291526.USD","LU0345770308.USD","IE00BLSP4239.USD","LU0345770993.USD","LU1674673428.USD","LU1074936037.SGD","IE00BJJMRZ35.SGD","LU1718418525.SGD","IE0002141913.USD","LU0098860793.USD","LU1221951129.SGD","LU0792757196.USD","LU1244550494.USD","BK4550","BK4568","LU1894683264.USD","LU1929549753.HKD","LU0795875169.SGD","LU1244550221.USD","LU0320765646.SGD","LU1732799900.SGD","LU1057294990.SGD","LU1061106388.HKD","LU0234572021.USD","LU1066051498.USD","LU2430703251.USD","LU2602419157.SGD","LU0289739699.SGD","LU1196500208.SGD","SG9999002224.SGD","LU1059921491.USD","LU1935042991.SGD","BK4533","BK4532","LU0985320562.USD"],"gpt_icon":0},{"id":"2533216372","title":"Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2533216372","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533216372?lang=en_us&edition=fundamental","pubTime":"2025-05-05 14:00","pubTimestamp":1746424800,"startTime":"0","endTime":"0","summary":"Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients  with locally advanced or borderline resectable pancreatic cancer. Median Overall Survival of 23 months from date of diagnosis [95% CI; 17 months – not reached]. Median Local Progression-Free Survival of 13.3 months from completion of radiation. Notable findings observed in exploratory biomarker analyses include:. An association between increased circulating tumor mutational burden  and LPFS and OS. CA19-9 normalization in 59% of patients in the study, and an association between CA19-9 normalization and OS. First patient injected in a new cohort that adds standard-of-care concurrent chemotherapy  to radiotherapy-activated JNJ-1900  and recruitment is ongoing. Investigators concluded that these results support further evaluation in a randomized study. “Patients with locally advanced or borderline resectable pancreatic cancer face a particularly urgent unmet need for therapeutic i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nanobiotix-announces-full-results-completed-060000624.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2468319806.SGD","LU0795875169.SGD","BK4504","IE00BN8TJ469.HKD","IE000M9KFDE8.USD","LU1244550221.USD","LU0345770993.USD","LU2347655156.SGD","IE00B19Z3B42.SGD","IE00B4R5TH58.HKD","LU2089984988.USD","LU2505996681.GBP","LU0203347892.USD","IE00B42XCP33.USD","IE00BJT1NW94.SGD","LU1244550494.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU2602419157.SGD","LU1032466523.USD","IE00B19Z3581.USD","IE00BLSP4452.SGD","JNJ","IE00BSNM7G36.USD","LU1221951046.USD","LU1267930813.SGD","LU1280957306.USD","SG9999001440.SGD","BK4559","LU2430703095.HKD","LU2112291526.USD","BK4533","LU0345769128.USD","LU0466842654.USD","LU2505996509.AUD","IE00BBT3K403.USD","LU1674673428.USD","IE00B1BXHZ80.USD","IE00BLSP4239.USD","BK4534","IE00BDGV0183.EUR","LU1066051225.USD","BK4568","LU0234572021.USD","LU1894683264.USD","BK4007","NBTX","LU1066053197.SGD","LU2430703178.SGD","LU1732799900.SGD"],"gpt_icon":0},{"id":"2533308255","title":"3 Cash-Heavy Stocks in the Doghouse","url":"https://stock-news.laohu8.com/highlight/detail?id=2533308255","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533308255?lang=en_us&edition=fundamental","pubTime":"2025-05-05 12:40","pubTimestamp":1746420035,"startTime":"0","endTime":"0","summary":"Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.Just because a business has cash doesn’t mean it’s a good investment. Luckily, StockStory is here to help you separate the winners from the losers. That said, here are three companies with net cash positions that don’t make the cut and some better choices instead.A trailblazer in the avocado industry, Calavo Growers  is a pioneering California-based provider of high-quality avocados and other fresh food products.Annual sales declines of 14.7% for the past three years show its products struggled to connect with the market. Revenue base of $688.3 million puts it at a disadvantage compared to larger competitors exhibiting economies of scale. Commoditized products, bad unit economics, and high competition are reflected in its low gross margin of 10.6%. At $27","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-cash-heavy-stocks-doghouse-044035629.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4534","BK4568","BK4532","LU1815336091.USD","BK4548","BK4104","MRNA","CVGW","BK4212","BK4501","BK4533","BK4585","DNOW","BK4551","BK4588","LU0757428866.USD","BK4139"],"gpt_icon":0},{"id":"2533630376","title":"iBio, Inc. Reports Strong Q3 2025 Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2533630376","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533630376?lang=en_us&edition=fundamental","pubTime":"2025-05-05 11:52","pubTimestamp":1746417160,"startTime":"0","endTime":"0","summary":"Ibio Inc ( ($IBIO) ) has released its Q3 earnings. Here is a breakdown of the information Ibio Inc presented to its investors. iBio, Inc. is a biot...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ibio-inc-reports-strong-q3-2025-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ibio-inc-reports-strong-q3-2025-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4568","LU2065732104.USD","BK4097","IBIO","PRGS"],"gpt_icon":0}],"pageSize":20,"totalPage":16,"pageCount":6,"totalSize":310,"code":"91000000","status":"200"}]}}